| dc.identifier.citation | [1]. Ali, MS, Chaudhary, MS, & Takieddin, MA 1999, ‘Simultaneous determination of metronidazole benzoate, methylparaben and propylparaben by high-performance liquid chromatography’, Drug Development on Industrial Pharmacy, vol.25, No. 10, pp. 1143-1147. [2]. Aulton, ME 1988, Pharmaceutics: the Science of Dosage Form Design, ELBS, Churchill Livingstone, United Kingdom. [3]. Allal, AS, Dulquerov, P, & Bieri, S 2000, ‘Assessment of quality of life in patients treated with accelerated radiotherapy for laryngeal and hypopharyngeal carcinomas’, Head Neck, vol22, pp. 288-293. [4]. Alpöz, E, Guneri, P, Onder, G, Cankaya, H, Kabasakal, Y, & Kose, T 2008, ‘The Efficacy of Xialine® in patients with Sjogren’s syndrome: a single-blind, cross-over study’, Clin Oral Invest, vol.12, pp. 165-172. [5]. British National Formulary 2009, British National Formulary. London. BMJ Group & RPS Publishing. [6]. Bolton, S 1997, Pharmaceutical Statistics Practical and Clinical Applications, Marcel Dekker Inc., New York. [7]. Burket, LW, Greenberg, MS, Glick, M, & Ship, JA 2008, Burket’s Oral Medicine, BC Decker Inc., Ontario. [8]. Davies, A & Finlay, IG 2005, Oral care in advanced disease. Oxford University Press London. [9]. Duxbury, AJ, Thakker, NS & Wastell, D G 1989, ‘A double-blind cross-over trial of a mucin-containing artificial saliva’, British Dental Journal, vol. 166, pp. 115-120. [10]. Fox, PC 1997, ‘Management of dry mouth’, Dental Clinics of North America,vol.41, no. 4, pp.863-875. [11]. Grotz, KA 2003, ‘Dental care for patients with antineoplastic radiotherapy of the head and neck’, Strahlenther Onkol, vol.179, pp. 275-278. [12]. Hatton, MN, Levine, MJ, Margarone, JE, & Aguirre, A 1987, ‘Lubrication and viscosity features of human saliva and commercially available saliva substitutes’, Journal Oral Maxillofac Surg, vol.45, pp. 496-499. [13]. Hahnel, S, Behr, M, Handel, G & Bürgers, R 2009, ‘Saliva substitutes for the treatment ofradiation-induced xerostomia-a review’, Support Care Cancer, vol.17, pp. 1331-1343. [14]. Joyston-Bechal, S & Kidd, EAM 1987, ‘The effect of three commercially available saliva substitutes on enamel in vitro’,Br. Dent. J,vol.63, pp. 187. [15]. Kelly, C 2001, ‘Sjogren’s syndrome and the respiratory system’, viewed 12 September 2002, <http://www. webhealth.co.uk /WbHealth_A-Z of Health/About Sjogren_s Syndrome>. [16]. Lund, W, (ed) 1994, The Pharmaceutical Codex, 12th edn. The Pharmaceutical Press, London. [17]. Levine, MJ 1993, ‘Development of artificial salivas’, Critical Reviews in Oral Biology and Medicine, vol.4, no. 3-4, pp.279-286. [18]. Leung, VWH & Darvell, BW 1997, ‘Artificial salivas for in vitro studies of dental materials’, Journal of dentistry, vol.25, no. 6, pp. 475-484. [19]. Myers, EN & Ferris, RL 2007, Salivary Gland Disoreders, Springer, New York. [20]. Momm, F, Muller, M, & Tsekos, A 2001, ‘Xerostomia after radiotherapy: more effective treatment by a mucin-containing spray, HNO,vol.49, pp. 831-836. [21]. Momm, F, Volegova-Neher, NJ, Schulte-Monting, J & Guttenberger, R 2005, ‘Different Saliva Substitutes for Treatment of Xerostomia Following Radiotherapy’, Stralenther Onkol,vol. 181, pp. 231-236. [22]. Philip, DDS 1997, ‘Management of dry mouth’, Dental Clinic of North America, vol. 41, no. 4, pp. 863 –875. [23]. Ramachandran, S, Chen, S & Etzler F 1999, ‘Rheological characterization of hydroxypropylcellulose gels’, Drug Development and Industrial Pharmacy,vol. 25, no. 2, pp. 153-161. [24]. Radus, TP & Gretchen, G 1983, ‘Determination of antimicrobial preservatives in pharmaceutical formulations using reverse-phase liquid chromatography’ Journal of pharmaceutical sciences, vol. 72, no. 3, pp. 221-224. [25]. Regelink, G, Vissink, A, Reitsema, H & Nauta, JM 1998, ‘Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia’, Quintessense International,vol. 29 no. 6, pp. 383-387. [26]. Sidney, HW & James, RS 1993, Good Manufacturing Practices for Pharmaceuticals. Marcel Dekker, Inc., New York. [27]. Smith, ME, & Morton, DG 2001, The Digestive System, Elsevier Health Sciences. [28]. Srivastava, LM 2004, Textbook of Biochemistry and Human Biology, Prentice-Hall of India Private Limited, New Delhi. [29]. Sweetman SC (edt.) 2007, Martindale, The Extra Pharmacopeia, Pharmaceutical Press, Council of the Royal Pharmaceutical Society of Great Britain. [30]. The United States Pharmacopeial convention 1995, The United States Pharmacopeia. The National Formulary, The United States Pharmacopeial Convention, Inc., Reckville. [31]. Tenevuo, JO 1981, Human Saliva: Clinical Chemistry and Microbiolog, CRC Press. [32]. Troy, DB (ed) 2006, Remington: The Science and Practice of Pharmacy, Lippincot William & Wilkins, Philadelphia. [33]. Vissink, A, ‘s-Gravenmade, EJ, Panders, AK, Vermey, A, Petersen, JK, Visch, LL & Schaub, RMH 1983, ‘A clinical comparison between commercially available mucin- and CMC- containing saliva substitutes’, Int. J. Oral Surg, vol. 12, pp. 232-238. [34]. Vissink, A, Waterman, HA, ‘s-Gravenmade, EJ, Panders, AK. and Vermey, A 1984, ‘Rheological properties of saliva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide’, Journal of Oral Pathology, vol. 13, pp. 22-28. | in_ID |
